NEXT GENERATION CONDOM CONTRACEPTION TO TACKLE SEXUALLY TRANSMITTED DISEASES & UNINTENDED PREGNANCIES
CASE STUDY (Filmed October 2023, June 2024)
Eudaemon Technologies
Australia
Eudaemon Technologies, an early-stage medtech company with a focus on sexual reproductive health, is developing a hydrogel condom to address the need for a better feeling, next generation condom, with the potential to improve user experience and address issues with traditional latex condoms.
“Over 1 million STI’s being diagnosed every day and up to 120 million unplanned pregnancies every year result in a $60 billion health burden across the globe”, says Co-Founder and Executive Director of Operations, Dr Simon Cook.
Formed in 2018, the company focuses on developing tough hydrogels as an alternative to address issues with odour, colour, and taste commonly associated with latex condoms. This technology can be loaded with small molecule drugs for flavours or anti-STI compounds, and was developed in response to a grant from the Bill and Melinda Gates Foundation to address unplanned pregnancies and STIs.
In 2022 Eudaemon Technologies was awarded AUD$1.5m in funding to advance the clinical trial of their next generation condom project, awarded by the Medical Research Future Fund (MRFF) funding from the Australian Government’s Clinical Translation and Commercialisation Medtech (CTCM) program, delivered by MTPConnect, and supported by MTAA.
Also, funding has come from NSW Health and The Office for Health and Medical Research.
According to Executive Chairman and Co-Founder Nick Northcott, the company has made significant progress in the past six months, including completing a pilot clinical trial involving 35 couples and achieving a major milestone.
“The completion of this Pilot Clinical Trial is a major milestone and value inflection point for the company. The Pilot Clinical data provides strong signal for safety, efficacy and consumer preference for Eudaemon’s Hydrogel Condom platform. We are now poised to move through scaling up our manufacturing, completing a Pivotal Clinical Trial prior to regulatory submission and then entering the market and commercialisation. A very exciting time for Eudaemon Tech as an Australian MedTech manufacturer.”, says Northcott.
Eudaemon Technologies is now focused on scaling up production and obtaining regulatory approval for commercialisation of their high-quality condoms. Once granted approval, the company is working towards scaling their manufacturing to produce the millions of units, with the ultimate aim to manufacture into the billions of high-quality condoms.
Eudaemon Technologies’ vision goes beyond the creation of a superior condom, as the company is ultimately contributing to an important global health cause. By assisting individuals in overcoming barriers to the consistent use of condoms through material innovation, the company endeavours to positively impact public health by mitigating the spread of STIs and reducing unplanned pregnancies on a global scale.
-
Nanoparticles & microparticles to combat antimicrobial resistance
Dr Anjana Jayasree is an emerging research leader in biomaterials, tissue engineering and nanotechnology, recognised internationally for her innovative work on antimicrobial nanoparticles and regenerative therapies. A Postdoctoral Research Fellow at The University of Queensland, she operates at the intersection of materials science, drug delivery and cellular biology, developing advanced metallic-based nanotechnologies to improve both human and animal health outcomes. Her expertise spans nanoparticle synthesis, cell–material interactions, and the design of sophisticated in vitro models to investigate soft-tissue integration, osseointegration, angiogenesis and biofilm formation.
-
Indigenous Australian health and ear disease
Professor Kelvin Kong feels incredibly fortunate to lead a fulfilling life surrounded by his loved ones. With a demonstrated history of service in the health industry, he brings a wealth of expertise across various sectors including clinical research, medical education, surgery, paediatrics, health policy, and Indigenous education. Kelvin started his university, residing at New College in 1992, which brings him fond memories. Graduating from medicine from the University of NSW, Kelvin continued his studies and became a fellow of the Royal Australasian College of Surgeons (RACS) and Australian Society of Otolaryngology, head & neck Society (ASOHNS).
-
Risk factors and prevention of respiratory infections and infectious diseases in children
A/Prof Hannah Moore OAM is an infectious disease epidemiologist; Co-Head of the Infectious Disease Epidemiology team within the Wesfarmers Centre of Vaccines and Infectious Diseases at The Kids Research Institute Australia and Associate Professor at the School of Population Health, Curtin University in Western Australia.
A/Prof Moore has been awarded more than $19M in competitive research grants, co-authored more than 140 papers, was TEDxPerth 2018 speaker, recipient of a WA Young Tall Poppy Award (2013) and the WA Premiers Science Early Career Scientist Award (2015). In 2024, she was honoured with a Medal of the Order of Australia for her service to epidemiology as a researcher.
